Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: A report from the Children's Oncology Group

Katherine Tarlock, Todd A. Alonzo, Pilar P. Moraleda, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Yaddanapudi Ravindranath, Beverly Lange, William G. Woods, Alan S. Gamis, Soheil Meshinchi

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Summary: Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a rare subtype associated with FLT3-internal tandem duplication (ITD) and poor outcomes. The clinical outcomes of paediatric patients with t(6;9) with and without FLT3-ITD treated on six consecutive cooperative trails were evaluated. In contrast to patients without t(6;9), those with t(6;9) had a significantly lower complete remission rate, higher relapse rate (RR), and poor overall survival (OS). Within t(6;9) patients, those with and without FLT3-ITD had an OS of 40% and 27% respectively (P > 0·9), demonstrating that t(6;9) is a high-risk cytogenetic feature in paediatric AML and its clinical impact is independent of the presence of FLT3-ITD.

Original languageEnglish (US)
Pages (from-to)254-259
Number of pages6
JournalBritish journal of haematology
Volume166
Issue number2
DOIs
StatePublished - Jul 2014

Keywords

  • Acute myeloid leukaemia
  • Clinical outcome
  • FLT3-ITD
  • Paediatric
  • T(6; 9)(p23; q34)

Fingerprint Dive into the research topics of 'Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: A report from the Children's Oncology Group'. Together they form a unique fingerprint.

  • Cite this

    Tarlock, K., Alonzo, T. A., Moraleda, P. P., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Ravindranath, Y., Lange, B., Woods, W. G., Gamis, A. S., & Meshinchi, S. (2014). Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: A report from the Children's Oncology Group. British journal of haematology, 166(2), 254-259. https://doi.org/10.1111/bjh.12852